Predicting pharmacokinetics with Optibrium and AstraZeneca
AstraZeneca
Nigel Greene
Director of Data Science & AI

Intellegens is a spin-out from the University of Cambridge with a unique Artificial Intelligence (AI) toolset that can train deep neural networks from sparse or noisy data. Their mission is to help their clients accelerate innovation by using their unique deep learning solutions to extract valuable information from existing processes and data. The technique, created at the Cavendish Laboratory, is encapsulated in Intellegens' first commercial product, Alchemite™. The cutting-edge deep learning algorithms that Alchemite™ is based on can see correlations between all available parameters, both inputs and outputs, in fragmented, unstructured, corrupt or even noisy datasets. The result is accurate models that can predict missing values, find errors and optimise target properties.
Showing 15 Intellegens Customer Success Stories
AstraZeneca
Nigel Greene
Director of Data Science & AI
Boeing
Lukas Jiranek
Boeing
Domino
Andrew Clifton
Director of Marking Materials and Test Engineering Team
Genentech
Fabio Broccatelli
Principal Scientist
GKN Aerospace
Marko Bosman
Chief Technologist
IFF
Dmitriy Chekmarev
Senior Research Investigator
Johnson Matthey
Lucideon
Richard Padbury
Lucideon
Matmatch
Melissa Albeck
Chief Executive Officer
NASA
Josh Stuckner
Materials Informatics Scientist
OCAS
Lode Duprez
Chief Scientific Officer
Optibrium
Matthew Todd
Professor of Drug Discovery at UCL School of Pharmacy and Founder
Rolls-Royce
The University of Sheffield
Welding Alloys Group
Mario Cordero
Project Leader
No matching case studies